Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 19% Improvement Relative Risk Ventilation 11% ICU admission -72% Elec et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 165 patients in Romania (March 2020 - May 2021) Higher ICU admission with remdesivir (p=0.01) Elec et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2022.03.015 Favors remdesivir Favors control
COVID-19 and Kidney Transplantation: The impact of remdesivir on renal function and outcome - a retrospective cohort study
Elec et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.03.015
Elec et al., COVID-19 and Kidney Transplantation: The impact of remdesivir on renal function and outcome - a retrospective.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.03.015
Mar 2022   Source   PDF  
  All Studies   Meta
Retrospective 165 hospitalized COVID-19+ kidney transplant patients, 38 treated with remdesivir, showing no significant difference in mortality, higher ICU admission, and lower ICU mortality. Subject to confounding by time with significant changes to SOC and treatment propensity during the study period.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir. This study is excluded in the after exclusion results of meta analysis: substantial confounding by time possible due to significant changes in SOC and treatment propensity during the study period.
risk of death, 19.3% lower, RR 0.81, p = 0.66, treatment 7 of 38 (18.4%), control 29 of 127 (22.8%), NNT 23.
risk of mechanical ventilation, 10.9% lower, RR 0.89, p = 0.73, treatment 8 of 38 (21.1%), control 30 of 127 (23.6%), NNT 39.
risk of ICU admission, 71.9% higher, RR 1.72, p = 0.01, treatment 18 of 38 (47.4%), control 35 of 127 (27.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Elec et al., 14 Mar 2022, retrospective, Romania, peer-reviewed, 9 authors, study period 1 March, 2020 - 31 May, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
COVID-19 and kidney transplantation: the impact of remdesivir on renal function and outcome - a retrospective cohort study
MD Florin Elec, Jesper Magnusson, Alina Elec, Adriana Muntean, Oana Antal, Tudor Moisoiu, Cristina Cismaru, Mihaela Lupse, Mihai Oltean
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.03.015
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
CONFLICT OF INTEREST There are no conflicts of interests to be reported
Adamsick, Gandhi, Bidell, Elshaboury, Bhattacharyya et al., Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19, J Am Soc Nephrol
Beigel, Tomashek, Dodd, Mehta, Zingman et al., ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 -Final Report, N Engl J Med
Benfield, Bodilsen, Brieghel, Harboe, Helleberg et al., Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study, Clin Infect Dis, doi:10.1093/cid/ciab536
Buxeda, Arias-Cabrales, Pérez-Sáez, Cacho, Pelegrin et al., Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19, Kidney Int Rep
Chen, Kuo, Lee, Yang, Wu et al., Incidence of Mortality, Acute Kidney Injury and Graft Loss in Adult Kidney Transplant Recipients with Coronavirus Disease 2019: Systematic Review and Meta-Analysis, J Clin Med
Deb, Reeves, Hopefl, Bejusca, ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential, Pharmaceuticals
Diaz, Christensen, Pusch, Goulet, Chang et al., Remdesivir and Mortality in Patients with COVID-19, Clin Infect Dis, doi:10.1093/cid/ciab698
Elec, Bolboacă, Muntean, Elec, Cismaru et al., Comparing the First and Second Wave of COVID-19 in Kidney Transplant Recipients: An East-European Perspective, Eur Surg Res, doi:10.1159/000517559
Elec, Oltean, Goldis, Cismaru, Lupse et al., COVID-19 after kidney transplantation: Early outcomes and renal function following antiviral treatment, Int J Infect Dis
Elens, Langman, Hesselink, Bergan, Moes et al., Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions, Ther Drug Monit
Garcia, Alonso, Camon, Cardozo, Albiach et al., Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19
Goldman, Lye, Hui, Marks, Bruno et al., -540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19, N Engl J Med
Group, Elm, Altman, Egger, Pocock et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Am J Transplant, doi:10.1016/S0140-6736(07)61602-X
Harvey, Morgan, Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents, Clin Pharmacol Ther
Heldman, Kates, Safa, Kotton, Georgia et al., Changing Trends in Mortality Among Solid Organ Transplant Recipients Hospitalized for Covid-19 During the Course of the Pandemic, Am J Transplant, doi:10.1111/ajt.16840
Jager, Kramer, Chesnaye, Couchoud, Sánchez-Álvarez et al., Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe, Kidney Int
Jayant, Reccia, Bachul, Al-Salmay, Pyda et al., The Impact of COVID-19 on Kidney Transplant Recipients in Pre-Vaccination and Delta Strain Era: A Systematic Review and Meta-Analysis, J Clin Med
Lo, Jordan, Arvey, Sudhamsu, Shrivastava-Ranjan et al., GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses, Sci Rep
Luke, Tomaszewski, Damle, Schlamm, Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD), J Pharm Sci, doi:10.1002/jps.22109
Maggiore, Abramowicz, Crespo, Mariat, Mjoen et al., How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion, Nephrol Dial Transplant
Martínez, Salas, Ballestín, Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review, Pharmaceuticals
Meshram, Kute, Patel, Banerjee, Navadiya et al., Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation, Transpl Infect Dis
Olender, Perez, Go, Balani, Eg et al., GS-US-540-5773 and GS-US-540-5807 Investigators. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care, Clin Infect Dis
Oltean, Søfteland, Bagge, Ekelund, Felldin et al., Covid-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic, Infect Dis (Lond)
Oltean, Ţăţulescu, Bondor, Slavcovici, Cismaru et al., Charlson's weighted index of comorbidities is useful in assessing the risk of death in septic patients, J Crit Care
Qin, Moore, Anjan, Rahamimov, Sifri et al., Risk of Breakthrough SARS-CoV-2
Spinner, Gottlieb, Criner, López, Cattelan et al., Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2020.16349
Villanego, Mazuecos, Pérez-Flores, Moreso, Andrés et al., Spanish Society of Nephrology COVID-19
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop